Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2236 to 2250 of 8936 results

  1. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

    In development Reference number: GID-TA10326 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

    In development Reference number: GID-TA10542 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Gosuranemab for treating progressive supranuclear palsy [ID1607]

    Awaiting development Reference number: GID-TA10553 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

    In development Reference number: GID-TA10573 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

    Awaiting development Reference number: GID-TA10604 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development Reference number: GID-TA10605 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Monofocal intraocular lenses for cataract surgery (provisional title)

    In development Reference number: GID-HTE10090 Expected publication date: TBC

    Health technology evaluations
    In development

  8. Surgical mesh for treatment of non-primary ventral hernias

    Awaiting development Reference number: GID-HTG10165 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [ID6733]

    Awaiting development Reference number: GID-TA11945 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

    In development Reference number: GID-TA11678 Expected publication date:  19 August 2026

    Technology appraisal guidance
    In development

  12. Heart valve disease presenting in adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)

    In development Reference number: GID-NG10457 Expected publication date: TBC

    NICE guideline
    In development

  13. Ex-situ machine perfusion devices for lung transplants

    In development Reference number: GID-HTE10084 Expected publication date: TBC

    Health technology evaluations
    In development

  14. Elinzanetant for Vasomotor symptoms [ID6544]

    Awaiting development Reference number: GID-TA11784 Expected publication date:  21 July 2027

    Technology appraisal guidance
    Awaiting development

  15. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    In development Reference number: GID-TA11565 Expected publication date:  21 May 2026

    Technology appraisal guidance
    In development